期刊名称：SLAS DISCOVERY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
DESCRIPTION
Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.
SLAS Discovery is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. SLAS Discovery is an official journal of SLAS.
Come Transform Research with SLAS: SLAS Discovery and SLAS Technology readers, authors, editors and reviewers are academic, commercial and government researchers, scientists and engineers who conduct research, and develop and implement new technologies. Together, these journals address the full spectrum of issues that are mission-critical to this important audience, enabling research teams to gain scientific insights; increase productivity; elevate data quality; reduce process cycle times; and enable research and development that otherwise would be impossible.
Click here for more information about SLAS Discovery’s editorial aims and scope.
SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).
AIMS AND SCOPE
Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.
SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success.
SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.
SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.
SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).
ABSTRACTING / INDEXING
BIOSIS database
Biomolecular Interaction Network Database (BIND)
Biotechnology Citation Index®
Chemical Abstracts Service (CAS)
Clarivate Analytics: BIOSIS Previews
Clarivate Analytics: Current Contents - Life Sciences
EMBASE/Excerpta Medica
EMBiology
Elsevier BV: BIOBASE
Index Medicus
InfoTrac (full text)
Prous Science Integrity®
PubMed: MEDLINE
Science Citation Index Expanded (Web of Science)
Scopus
Instructions to Authors
SLAS Author Instructions | 저자 지침 | 作者须知 | 作者須知 | 著者への指示
SLAS Discovery SAGE Track System (Submit a Manuscript)
Average time from submission to first decision: 29 days.
Editorial Board
EDITOR-IN-CHIEF
ASSOCIATE EDITORS
| Marc Bickle, PhD |
Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany |
| Christian Parker, PhD |
Novartis Institutes for Biomedical Research, Basel, Switzerland |
| Kirti Sharma, PhD |
Janssen Research & Development, Spring House, PA, USA |
REVIEWS EDITOR
SCIENTIFIC ADVISORS
| Ricardo Macarrón, PhD |
GlaxoSmithKline R&D, Collegeville, PA, USA |
| Lorenz M. Mayr, PhD |
GE Healthcare Life Sciences, Amersham, UK |
| D. Lansing Taylor, PhD |
University of Pittsburgh, Pittsburgh, PA, USA |
EDITORIAL BOARD
| James Beasley, PhD |
Venenum Biodesign, Hamilton, NJ, USA |
| Christine Brideau, BS |
WuXi AppTec, Holmdel, NJ, USA |
| Mei Ding, PhD |
AstraZeneca, Gothenburg, Sweden |
| Hakim Djaballah, PhD |
Keren Therapeutics, New York, NY, USA |
| Marc Ferrer, PhD |
NIH Chemical Genomics Center, Rockville, MD, USA |
| Robert A. Goodnow, Jr, PhD |
Pharmaron, Boston, MA, USA |
| Charles Hart, PhD |
Threshold Pharmaceuticals, South San Francisco, CA, USA |
| Rob Howes, PhD |
AstraZeneca, Gothenburg, Sweden |
| David J. Kahler, PhD, PMP |
NYU High-Throughput Biology Laboratory, New York, NY, USA |
| Jeroen Kool, PhD |
Vrije Universiteit Amsterdam, Netherlands |
| Martin Main, PhD |
Medicines Discovery Catapult, Alderley Park, Cheshire, UK |
| Jose Julio Martin-Plaza, PhD |
GlaxoSmithKline, Tres Cantos, Spain |
| Larry Mattheakis, PhD |
Protagonist Therapeutics, Milpitas, CA, USA |
| James McGee, PhD |
Eli Lilly & Company, Indianapolis, IN, USA |
| Joseph McGivern, PhD |
Amgen Inc., Thousand Oaks, CA, USA |
| Robert Nadon, PhD |
Department of Human Genetics, McGill University, McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada |
| Katja Remlinger, PhD |
GlaxoSmithKline, Raleigh-Durham, NC, USA |
| Mariafrancesca Scalise, PhD |
University of Calabria, Cosenza, Italy |
| Timothy Spicer, MSc |
The Scripps Research Institute, Jupiter, FL, USA |
| Masoud Vedadi, PhD |
University of Toronto, Canada |
| Francisca Vicente, PhD |
Fundación MEDINA, Granada, SPAIN |
| Andreas Vogt, PhD |
University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA |
| Mark Wade, PhD |
Astex Pharmaceuticals, Cambridge, UK |
DIRECTOR OF PUBLISHING
| Nan Hallock |
Society for Laboratory Automation and Screening - Manitowoc, WI, USA |
|
